Erosive Esophagitis Clinical Trial
Official title:
A Randomized Double-blind, Double Dummy, Active Comparator-controlled Dose-finding Study in Patients With Erosive Esophagitis Due to Gastro-esophageal Reflux Disease (GERD) Los Angeles Grade C or D, and Patients With at Least Partial Symptom Response But Endoscopically Still Unhealed After 8 Weeks History of Standard Treatment Healing Course With Proton-pump Inhibitor (PPI), to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole, and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Verified date | October 2023 |
Source | Cinclus Pharma AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.
Status | Completed |
Enrollment | 248 |
Est. completion date | September 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Body mass index (BMI) = 18 and = 40 kg/m^2 at screening. 2. Gastro-esophageal reflux disease with endoscopically confirmed esophagitis: - LA grade C or D =7 days before randomization (with or without historical PPI treatment) or - LA grade A or B =7 days before randomization and history of treatment with the standard healing course of PPI for minimum of 8 weeks prior to screening and =7 days of non-treatment during this period and at least partial symptom response during the minimum of 8 weeks of PPI treatment. 3. Willing and able to comply with all aspects of the protocol (including capsule swallowing, diary completion, etc.). 4. Capable of signing informed consent form. Exclusion Criteria: 1. History or presence of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease or disorder. 2. Patients with so-called "alarm features" in symptomatology, like odynophagia, severe dysphagia, bleeding, weight loss, anemia, and blood in stool pointing to a possible malignant disease of the gastrointestinal (GI) tract. 3. Present clinically significant psychiatric diagnosis. 4. History of malignancy of any organ system. 5. Presence of esophageal ulcer, stricture, BarrettĀ“s esophagus or suspected esophagitis secondary to infection, inflammatory disease, ingestion of erosive chemicals or history of any surgical or medical condition which might significantly alter the Gastro-oesophageal reflux disease (GERD) status or the absorption, distribution, metabolism or excretion of drugs. 6. Known severe atrophic gastritis. 7. Any planned major surgery within the duration of the study. 8. History of a positive result for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), antibody to Hepatitis B core antigen (anti-HBcAg), or antibody to Hepatitis C virus (anti-HCV) or presence of these findings on screening. 9. History of long QTc syndrome (e.g. QTc =450 ms for males and =470 ms for females). 10. Cardiac arrhythmias or any clinically significant abnormalities in the resting 12-lead ECG at the time of screening, as judged by the Investigator. 11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity. 12. Current or history of alcohol, drug abuse and/or use of anabolic steroids within 2 years prior to screening. 13. Women who are pregnant or breastfeeding. 14. Patients who have previously participated (completed or withdrawn) in this study CX842A2201. |
Country | Name | City | State |
---|---|---|---|
Bulgaria | Medical Centre Asklepii | Dupnitsa | |
Bulgaria | Medical Center Medconsult Pleven | Pleven | |
Bulgaria | DCC-1 Sliven | Plovdiv | |
Bulgaria | MHAT "Kaspela" | Plovdiv | |
Bulgaria | Medical Center Prolet EOOD | Ruse | |
Bulgaria | Diagnostive Consultative Center-1 Sliven | Sliven | |
Bulgaria | Medical Center Hera - Gastroenterology office | Sliven | |
Bulgaria | 2-nd MHAT | Sofia | |
Bulgaria | DCC XIV Sofia | Sofia | Sofia-Grad |
Bulgaria | DCC XIV Sofia | Sofia | Sofia-Grad |
Bulgaria | Medical Center Excelsior | Sofia | Sofia-Grad |
Bulgaria | Medical Center Excelsior | Sofia | |
Bulgaria | Medical Center Hera - Gastroenterology office | Sofia | |
Bulgaria | MHAT "Sveti Ivan Rilski" - Sofia | Sofia | |
Bulgaria | Medical Center New Rehabilitation Center EOOD | Stara Zagora | |
Bulgaria | Medical Center "Biomed 99" Ltd | Vidin | |
Bulgaria | Mhat "Hristo Botev" | Vratsa | |
Czechia | ResTrial GastroEndo s.r.o. | Praha 4 | |
Georgia | LTD"Brothers" | Batumi | Ajaria |
Georgia | A. Aladashvili clinic LLC | Tbilisi | |
Georgia | Emergency Cardiology Center named by acad. G. Chapidze | Tbilisi | |
Georgia | LTD Israeli-Georgian Medical Research Clinic "Helsicore" | Tbilisi | |
Georgia | LTD TSMU and Ingorokva High Medical Technology University Clinic | Tbilisi | |
Hungary | Bekes Megyei Kozponti Korhaz, Dr.Rethy Pal Tagkorhaz | Békéscsaba | Békés |
Hungary | ClinExpert Kft. | Budapest | Pest |
Hungary | Pannonia Maganorvosi Centrum Kft | Budapest | |
Hungary | Szegedi Tudomanyegyetem Általános Orvostudományi Kar | Szeged | Csongrád |
Poland | NZOZ "Centrum Medyczne KERMED" | Bydgoszcz | Kujawsko-pomorskie |
Poland | Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi | Lodz | Lódzkie |
Poland | Oswiecimskie Centrum Badan Klinicznych Medicome Sp. z o.o. | Oswiecim | |
Poland | ETG Skierniewice | Skierniewice | |
Poland | Twoja Przychodnia - Szczecinskie Centrum Medyczne | Szczecin | |
Poland | Centrum Medyczne Melita Medical | Wroclaw | Dolnoslaskie |
Poland | EuroMediCare Szpital Specjalistyczny z Przychodnia | Wroclaw | |
Poland | EuroMediCare Szpital Specjalistyczny z Przychodnia | Wroclaw | |
Poland | ETG Zamosc | Zamosc | |
Serbia | Zvezdara University Medical Center | Belgrade | |
Ukraine | Oblasna komunalna ustanova "Chernivetska oblasna klinichna likarnia" | Chernivtsi | Chernivets'ka Oblast' |
Ukraine | KNP "Odeska oblasna klinichna likarnia" Odeskoi oblasnoi rady" | Odesa | Odes'ka Oblast' |
Ukraine | Medychnyi Tsentr TOV "KHELS KLINIK" - viddil Gasrtroenterology, Hepatology and Endocrinology | Vinnytsia | Vinnyts'ka Oblast' |
Ukraine | KU "6-A miska klinichna likarnia" | Zaporizhzhia | Zaporiz'ka Oblast' |
United States | Genesis Clinical Research - Tampa | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Cinclus Pharma AG | Parexel |
United States, Bulgaria, Czechia, Georgia, Hungary, Poland, Serbia, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients With Esophageal Mucosa Healing | The healing of erosive esophagitis due to gastro-esophageal reflux disease (GERD) was assessed. It supported the dose selection X842,through the assessment of healing of erosive esophagitis due to GERD based on endoscopic assessment after 4 weeks of treatment. The dose that would lead to having 85% of the patients have esophageal mucosa healing after 4 weeks of treatment. Following the endoscopic evaluation, all patients received subsequent 4 weeks of open-label treatment with lansoprazole. Repeated symptom evaluation was assessed during this period to detect the symptom pattern. Endoscopy evaluation at 4 weeks was based on the level and duration of acid control achieved with X842. Symptom evaluation was assessed using the validated patient-reported outcome (PRO) QOLRAD (Heartburn version) and patient diaries (RESQ-eDiary). | Week 4 | |
Secondary | Number of Patients With Adverse Events (AEs) | The safety and tolerability of the four dose levels of X842 and Lansoprazole were evaluated, where Lansoprazole served as the active comparator. Here TEAE- Treatment-emergent adverse event, ADR- Adverse drug reaction, SAE- Serious adverse event, and AESI- Adverse events of special interest. | From Screening (Day -7 to Day 0) until Week 8 | |
Secondary | Percentage of Heartburn-Free 24-hour Days | Heartburn-free in a 24-hour day was a day where patient reported having no burning feeling or pain behind breast or in center of upper stomach for both morning and evening. Percentage of heartburn-free 24-hour days based on eDiary(Reflux Symptom Questionnaire electronic Diary: RESQ-eDiary) was evaluated. Reflux-related symptom pattern was evaluated during initial 4 weeks of treatment with four dose levels of X842 and with Lansoprazole, and symptom pattern during subsequent additional 4 weeks Lansoprazole treatment in open-label. Modified RESQ-eDiary was validated self-reported questionnaire electronic symptom diary. mRESQ-eD has 3 domains [i.e. Heartburn (min-max: 0-10), Other GERD signs/symptoms (min-max:0-15) and Regurgitations/Reflux (min-max: 0-8)]. Endoscopy followed by lansoprazole administration and symptom evaluation using PRO QOLRAD (Heartburn version) and patient diaries assessed acid control achieved with X842 at 4 weeks. | Weeks 1 and 8 | |
Secondary | Percentage at Most-mild Heartburn 24-hour Days | Heartburn with at most mild symptoms in a 24-hour day was defined as a day where the patient reported having either no symptoms, very mild symptoms, or mild burning feeling or pain behind the breast or in the center of the upper stomach (score between 0-2) for both morning and evening. Heartburn assessed the severity as per the following scores (0=Did not have, 1=Very mild, 2=Mild, 3=Moderate, 4=Moderately severe, 5=Severe). Here higher scores represent the worst outcome, whereas lower scores represent the better outcome. After endoscopic evaluation, patients received lansoprazole, and symptom evaluation was conducted to detect patterns. Endoscopy evaluation at 4 weeks was based on the level and duration of acid control achieved with X842. Symptom evaluation involved the use of validated PRO QOLRAD (Heartburn version) and patient diaries. | Weeks 1 and 8 | |
Secondary | Investigator Assessment of Symptoms by Frequency and Severity | Investigator assessed severity and frequency of patients' heartburn, regurgitation, and dysphagia in 7 days. Assessment included both severity grade (for severity, items were coded: none, mild, moderate, severe where none represented no complaints, severe represented incapacitating symptoms) and frequency (for frequency, a 7-graded Likert scale was used, ranging from none to all of time) of symptoms. Symptoms were scored as follows: none (no complaints), mild (aware of symptom, but easily tolerated), moderate (discomforting symptom, sufficient to cause interference with normal daily activities and/or sleep), severe (incapacitating symptom, with inability to perform normal daily activities and/or sleep). Following endoscopic evaluation, patients received lansoprazole and underwent symptom evaluation using validated PRO QOLRAD (Heartburn version) and patient diaries.Here, for frequency- All of the time and None of the time, and for symptoms- none and severe data has been presented. | Weeks 1 and 8 | |
Secondary | Change From Baseline in Quality of Life in Reflux and Dyspepsia (QOLRAD) Score | Reflux-related symptom pattern was evaluated during initial 4 weeks of treatment with 4 dose levels of X842 and with Lansoprazole, and symptom pattern during subsequent additional 4 weeks of open-label treatment with Lansoprazole. Heartburn version of QOLRAD is a disease-specific instrument containing 25 questions addressing concerns associated with gastrointestinal symptoms. Questions were rated on a seven-grade (1-7) Likert scale, where a score of 1 represented low quality of life, and as score increased, the patient's condition was considered better. Questions were categorized into 5 domains: emotional distress, sleep disturbance, vitality, food/drink problems, and physical/social functioning. The score in each domain was calculated as the mean of all items in that domain. The score ranges from 1 to 175, higher scores mean a better outcome. After endoscopic evaluation, patients received lansoprazole and underwent symptom evaluation using validated PRO QOLRAD and patient diaries. | Baseline, Weeks 1, and 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01452776 -
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
|
Phase 3 | |
Recruiting |
NCT05587309 -
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT04124926 -
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT01459367 -
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
Completed |
NCT01499368 -
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
|
Phase 3 | |
Not yet recruiting |
NCT04613895 -
Treatment Effect According to Timing of Administration of DWP14012 40 mg
|
N/A | |
Recruiting |
NCT02615184 -
A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children
|
Phase 2 | |
Completed |
NCT02456935 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT02028663 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 2 | |
Completed |
NCT03006874 -
Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT02388724 -
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT01865825 -
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
|
N/A | |
Completed |
NCT02679508 -
Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
|
Phase 4 | |
Recruiting |
NCT06391177 -
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily
|
Phase 1 | |
Completed |
NCT05050188 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008
|
Phase 1 | |
Completed |
NCT01874535 -
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
|
Phase 4 | |
Completed |
NCT00206180 -
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
|
Phase 4 | |
Completed |
NCT01642615 -
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
|
Phase 2 | |
Completed |
NCT01630746 -
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
|
Phase 3 |